Clinical trials
Relapsed or Refractory Plasma Cell Neoplasms clinical trials
Below are recruiting relapsed or refractory plasma cell neoplasms clinical trials, each written for real people, not researchers. We’re tracking 1,686 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06537843RecruitingPhase 2
Venetoclax, cytarabine and metformin for AML
This trial tests a combination of three drugs – venetoclax, cytarabine, and metformin – for adults with AML who cannot receive standard high-dose chemotherapy. It aims to see if this gentler mix can help control the leukemia with fewer side effects.
BelémAges 18 years+ - NCT06539182RecruitingPhase 2
DZD8586 for relapsed or refractory CLL/SLL
This trial tests a new oral drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if it can help control the disease.
Hefei, AnhuiAges 18 years+ - NCT06541327Recruiting
Cell therapy for returning lymphoma study
This study collects data from adults with lymphoma that has come back or not improved after treatment, who have received or are receiving special cell therapies. The goal is to learn more about how these treatments work in real life.
ShanghaiAges 18 years+ - NCT06563596RecruitingPhase 2
Study of epcoritamab, zanubrutinib, and rituximab for relapsed lymphoma
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06567197Recruiting
MS treatment with stem cell transplant in the Netherlands
This trial studies a stem cell transplant treatment for relapsing-remitting multiple sclerosis (RRMS). It aims to see how well this therapy works for people in the Netherlands who have already been approved for it.
AmsterdamAges 18–65 - NCT06569147RecruitingPhase 1/Phase 2
Elranatamab for AL amyloidosis that has returned or not responded
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT06586177Recruiting
Study on Long-Term Effects of B Cell Therapies for MS
This study looks at how B cell therapies (a type of medicine for MS) create a long-lasting effect in people with relapsing-remitting multiple sclerosis. It aims to understand how these treatments work over time so doctors can better predict benefits and risks.
DüsseldorfAges 18–60 - NCT06588478RecruitingPhase 2
Study of pirtobrutinib for CLL or SLL
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
Chandler, ArizonaAges 18 years+ - NCT07689058RecruitingPhase 2
CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
Rawalpindi, Punjab ProvinceAges 18 years+ - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT06613334Recruiting
Voice recordings to predict schizophrenia relapse
This study tests whether voice recordings can help predict when someone with schizophrenia might have a relapse. It is for people who are stable now and take certain medications.
Paris, ParisAges 18–60 - NCT06644118RecruitingPhase 1
Study of OL-101 for people with relapsed or refractory multiple myeloma
This trial tests a new treatment called OL-101 for people whose multiple myeloma has come back or stopped responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. It aims to see if OL-101 can help control the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06660368RecruitingPhase 2
A study of a drug combo for relapsed or refractory AML
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
Tampa, FloridaAges 18–80 - NCT06680752RecruitingPhase 1/Phase 2
A car-t cell therapy trial for AML or MDS
This trial tests a new CAR-T cell therapy, ARD103, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It aims to see if this therapy can help control the disease.
Charlotte, North CarolinaAges 18 years+ - NCT05160584Recruiting
Real-world treatment study for relapsed or refractory myeloma
This study follows people with multiple myeloma that has come back or stopped responding to treatment, and looks at how current care is used in real life. It may include people starting talquetamab, and aims to understand outcomes and treatment patterns outside of strict experimental settings.
LeobenAges 18 years+ - NCT05091424RecruitingPhase 1
Mosunetuzumab with or without venetoclax for CLL
This Phase 1 study tests whether mosunetuzumab alone or with venetoclax is safe and effective for people with chronic lymphocytic leukemia (CLL) that came back or did not respond to prior treatment. It may help by controlling the CLL immune system response while also studying dosing and side effects.
Rochester, MinnesotaAges 18 years+ - NCT07384715RecruitingPhase 1
GEN3018 for AML or high-risk MDS
This trial tests a new drug called GEN3018 for people with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
AarhusAges 18 years+ - NCT07136545RecruitingPhase 1/Phase 2
HCB101 plus pembrolizumab for advanced head and neck cancer
This trial tests a new drug, HCB101, combined with the immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread and is no longer responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
Taoyuan, Guishan DistrictAges 18 years+ - NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Birmingham, AlabamaAges Up to 21 years - NCT06713837RecruitingPhase 3
Comparing treatments for relapsed or hard-to-treat AML
This trial compares two types of chemotherapy for people with acute myeloid leukemia (AML) that came back or did not get better after initial treatment. Your doctor will help decide if you can join, and you will be randomly assigned to either a lower-intensity or a higher-intensity treatment plan.
BrnoAges 18 years+ - NCT06737523RecruitingPhase 1
A new combination therapy for relapsed or refractory AML
This trial tests a three-drug combination for patients whose AML has returned or not responded to prior treatment. It aims to see if adding a new drug (Chiglitazar) to standard treatments (Venetoclax and Azacitidine) can help control the leukemia.
Xiamen, FujianAges 18 years+ - NCT06741722RecruitingPhase 2
Study of mitoxantrone liposome combo for relapsed or refractory AML
This trial tests a new combination of drugs (mitoxantrone liposome plus others) for people with AML that has returned or hasn't responded to treatment. The goal is to see if the combination is safe and effective.
BeijingAges 18–75 - NCT06747156RecruitingEarly Phase 1
mRNA medicine for refractory autoimmune diseases
This trial tests a new type of medicine (ABO2203) that trains your immune system to attack the cells causing your autoimmune disease. It's for people who haven't gotten better with standard treatments.
Wuhan, HubeiAges 18 years+ - NCT06756061RecruitingPhase 2
Ruxolitinib and steroids for chronic graft-versus-host disease
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
Seoul, Banpo-daero/Seocho-guAges 19 years+
Hear when a new Relapsed or Refractory Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory plasma cell neoplasms?
- Yes. Clin2 currently lists 1,686 recruiting relapsed or refractory plasma cell neoplasms studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory plasma cell neoplasms trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory plasma cell neoplasms trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
- Refractory Plasma Cell Myeloma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Multiple Myeloma and Malignant Plasma Cell Neoplasms
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.